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Abstract
Background: Prognostic factors aid in the stratification and treatment of cancer. This study evaluated the
prognostic significance of human epidermal growth factor receptor (HER) family members (HER1–4) expression in
patients with operable pancreatic cancer.
Methods: The expression of individual HER proteins in patient tissue specimens was detected by
immunohistochemistry staining. Patient follow-up time was between 1.0 and 78.1 months.
Results: Positive expression of HER1, HER2, HER3 and HER4 was detected in 41.4, 60.0, 24.3 and 65.7% of cases,
respectively. Kaplan–Meier analysis revealed that HER3 positive expression was associated with decreased median survival
time (12.0 vs. 25.6 months for HER3 positive and negative groups, respectively; P= 0.013). Cox’s regression confirmed that
positive HER3 expression was an independent predictor of poor survival (RR = 3.684, P= 0.001). In contrast, HER4 negative
patients had a significantly decreased median survival time when compared with HER4 positive patients (11.4 vs. 25.
6 months, respectively; P= 0.027). However, HER4 was not an independent predictor of survival. No significant association
between HER1 or HER2 expression and survival was observed (P = 0.626 & P= 0.859, respectively).
Conclusions: HER3 is an independent prognostic marker for patients with operable pancreatic cancer. HER4 may also be
of potential prognostic value in this disease and deserves further attention.
Keywords: Pancreatic cancer, Prognosis, HER1, HER2, HER3
Background
Pancreatic cancer is the fourth leading cause of cancer-
related death in the United States with a 5-year survival
rate of only 5% [1]. The majority of patients are diagnosed
in the late stages of disease both because of a lack of ef-
fective early detection methods and a lack of recognizable
symptoms. Although surgical resection offers the best
hope for long-term survival [2], post-surgery relapse or
metastasis are inevitable [3]. As a result, there is an urgent
need to discover new biomarkers to aid in predicting
prognosis and developing curative strategies against pan-
creatic cancer.
The human epidermal growth factor receptor (HER)
family belongs to the tyrosine kinase receptor superfamily.
It includes four highly homologous members, HER1,
HER2, HER3 and HER4. HER family proteins and their as-
sociated downstream signaling networks regulate cellular
activities such as gene expression, mitosis, differentiation,
proliferation, survival, migration, invasion, and apoptosis
[4, 5]. In the clinic, targeted therapy directed at HER fam-
ily proteins is well established. The small molecule HER1
tyrosine kinase inhibitor gefitinib has been used in the
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fist-line treatment of advanced non-small cell lung cancer
associated with HER1 mutation [6]. The anti-HER1
monoclonal antibody cetuximab has been used in the tar-
geted therapy of head and neck squamous cell carcinoma,
colorectal cancer and advanced non-small cell lung cancer
[7–9]. The anti-HER2 monoclonal antibody trastuzumab
has been used in the targeted therapy of HER2-positive
advanced breast and gastric cancers [10, 11]. The bispeci-
fic antibody MM-111 and anti-HER3 antibody patritumab
both inhibit the activation of HER3 and demonstrate anti-
tumor activity [12, 13], while HER4 represents a potential
molecular target for melanoma [14]. HER family proteins
are also of important clinical significance in determining
prognosis in a variety of solid tumors. HER1 overexpres-
sion is associated with increased depth of invasion, vascu-
lar invasion, and poor prognosis in esophagus squamous
cell carcinoma [15]. HER2 overexpression is associated
with shorter time to progression and decreased survival in
breast cancer [16]. HER2 and HER3 are both predictors of
poor outcome in gastric cancer [17, 18]. Data on the prog-
nostic value of HER4 in solid tumors are less clear. How-
ever, a study by Barnes et al. demonstrated that absence of
HER4 expression could predict the recurrence of ductal
carcinoma in situ of the breast [19].
The prognostic significance of HER family protein expres-
sion in operable pancreatic cancer remains unclear. This
study was to investigate the expression status of HER family
proteins (HER1–4) in tissue specimens obtained from pa-
tients with operable pancreatic cancer. A detailed analysis of
the relationship between HER family expression status and
patient survival was performed, and factors that represented
independent predictors of prognosis were identified.
Methods
Cell culture, antibodies and other reagents
The AsPC-1 human pancreatic cancer cell line was ob-
tained from the experimental center of Beijing Friendship
Hospital. Cells were cultured in Dulbecco’s Modified Eagle
Medium supplemented with 10% fetal bovine serum and
maintained at 37 °C in a humidified incubator containing
5% CO2.
For western blotting, rabbit monoclonal antibodies against
phospho-HER3 (Y1289) and beta-actin were purchased
from Cell Signaling Technology. The anti-HER3 monoclonal
therapeutic antibody (clone 3D4) was obtained from Beijing
Cotimes Biotech Co., Ltd. and used at 2.5 μl/ml for 0.5 h.
The anti-human HER2 antibody (Herceptin) was purchased
from Shanghai Roche Pharmaceuticals co., LTD and was
used at 7ul/ml for 2.5 h.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
To perform MTT-based cell proliferation assays, cells in
the logarithmic phase of growth were seeded in triplicate
in 96-well plates at a density of 0.5 × 104 cells/well. Cells
were then treated with serially diluted anti-HER3 mono-
clonal antibody (clone 3D4, Beijing Cotimes Biotech Co.,
Ltd.) for 48 h, after which 10 μl of a 5 mg/ml stock of
MTT (Sigma) was added to the wells. The cells were in-
cubated at 37 °C for an additional 4 h, and the reaction then
stopped by treating the cells with 150 μl of DMSO for
5 min. The optical density was then measured at 490 nm. A
control group that received no antibody treatment was used
as a reference for calculating relative cell survival.
Western blotting analysis
AsPC-1 human pancreatic cancer cell line were lysed,
and cell lysates were resolved on 7.5% SDS–PAGE gels,
and the proteins then electrophoretically transferred
onto nitrocellulose membranes. Blotting membranes
were blocked for 1 h and incubated with primary anti-
body overnight at 4 °C. Goat anti-β-actin was used as a
loading control. Membranes were washed with Tris-
buffered saline/0.5% Tween 20 and then incubated with
anti-rabbit (for primary antibodies against HER family
proteins) or goat (for the primary β-actin antibody) lgG
secondary antibody conjugated to horseradish peroxid-
ase. For protein visualization, nitrocellulose membranes
were incubated for 2–3 mins with Western HRP Sub-
strate and the chemiluminescent product then detected
following exposure to KODAK film.
Patients
Seventy patients who underwent surgical resection for pri-
mary pancreatic cancer at the Beijing Friendship Hospital
between January 2008 and December 2012 were enrolled
in this study. Complete clinical, pathological and follow-
up data were obtained for all patients. Clinical data includ-
ing age, sex, family tumor history, smoking and drinking
history, and CA 19-9 score were recorded. Pathological
data including tumor location, margins, histology grade,
histopathology type, primary tumor (T), lymph nodes (N)
and the number of positive lymph nodes were also
collected. The median age of all patients was 62 years,
with a range of 18–80 years. Follow-up time was between
1.0 and 78.1 months. The deadline of follow-up was
December 31, 2015, or the data of patient death.
Immunohistochemistry (IHC) and tissue scoring
Five-micron-thick sections were prepared from formalin-
fixed, paraffin-embedded tissues derived from surgically
resected pancreatic cancer specimens. Immunohistochem-
ical samples were individually assessed without knowledge
of patient outcome. Prior to staining, each slide was
deparaffinized and heated in citrate buffer. After cooling
and rinsing in Tris buffer, immunohistochemical staining
was performed using an automated IHC autostainer.
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The kits for the detection of HER family proteins
(HER1–4) were purchased from Santa Cruz Biotechnology.
Inc. Anti-HER1 antibody (sc-03, Rabbit polyclonal IgG),
anti-HER2 antibody (sc-284, Rabbit polyclonal IgG), anti-
HER3 antibody (sc-285, Rabbit polyclonal IgG), and anti-
HER4 antibody (sc-283, Rabbit polyclonal IgG) were used
at a dilution of 1:200, 1:200, 1:20, and 1:40, respectively.
Detection of HER family proteins was performed using a
secondary mouse anti-immunoglobulin antibody linked to
biotin in conjunction with streptavidin linked to horserad-
ish peroxidase.
Slides were scored independently by two individuals
using a 4-point intensity scale system, and any discrep-
ancies in scores were resolved by an arbiter. HER protein
staining was scored as either 0, 1+, 2+, or 3+, the cyto-
plasm and membrane-staining intensity and pattern
were evaluated according to the following scale [20]: no
staining is observed or is observed in less than 10% of
the tumor cells (score 0), weak staining is detected in
10% or more tumor cells (score 1+), moderate staining is
observed in 10% or more tumor cells (score 2+) and
strong staining is observed in 10% or more tumor cells
(score 3). Scores of 0, 1+ and 2+ were taken to represent
negative protein expression, while a score of was 3+ was
taken to represent positive protein expression.
Statistical analysis
Survival time was calculated in months from the date of
surgery to the date of death, or date of final contact as
of December 31, 2015. The survival times of patients be-
tween different subgroups were compared using the log-
rank test. The Chi-square test was used to test associa-
tions between the expression of HER proteins and clini-
copathological parameters. The Kaplan–Meier method
was used for survival analysis and the log-rank test to
determine the statistical significance of differences be-
tween survival curves. Relative risks associated with
HER positive expression were calculated by Cox’s Mul-
tiple Regression analysis. A P value of less than 0.05 was
considered significant. Statistical analysis was performed
using SPSS 11.0 software (SPSS Inc., Chicago, IL, USA).
Results
HER3 expression in pancreatic cancer cells and the
inhibitory effects of anti-HER3 antibody
Given the significant association observed between HER3
expression and poor survival in patients with many solid
tumors, we wished to determine whether this receptor
was expressed in pancreatic cancer cells in vitro and, if so,
to determine its role in cellular proliferation. High levels
of pHER3 expression were confirmed in the AsPC-1 pan-
creatic cancer cell line by western blotting, anti-HER3
monoclonal antibody (3D4) and anti-HER2 monoclonal
antibody (trastuzumab) significantly down-regulated the
expression of pHER3, and two drug combination showed
synergistic inhibitory effect (Fig. 1a). Furthermore, the
treatment of AsPC-1 cells with increasing concentrations
of anti-HER3 monoclonal antibody (3D4) resulted in sig-
nificant inhibition of cellular proliferation at concentra-
tions equal to 20 ug/ml or 50 μg/ml (P < 0.05), as
determined by an MTTassay (Fig. 1b).
Expression of HER family proteins in pancreatic tissue
specimens
IHC analysis was performed to determine the expression
of HER family proteins in tissue specimens obtained from
70 patients with operable pancreatic cancer. For each re-
ceptor, tissue specimens were assigned a score according
to the cytoplasm and membrane-staining intensity. Ana-
lysis of intensity scores revealed that HER1, HER2, HER3
and HER4 exhibited positive staining in 41.4, 60.0, 24.3
and 65.7% of cases, respectively. Representative images of
immunostaining related to HER1, 2, 3 & 4 expression in
pancreatic cancer tissues are shown in Fig. 2.
Analysis of the relationship between patient
characteristics and median survival time in operable
pancreatic cancer
The relationship between the clinical/pathological char-
acteristics and median survival time in patients with op-
erable pancreatic cancer are showed in Table 1.
Differences in median survival times (MSTs) between
subgroups were evaluated using the log-rank test. The
Fig. 1 pHER3 expression in AsPC-1 cells and the inhibitory effect of anti-HER3 monoclonal antibody (3D4). a. pHER3 was overexpressed in the
AsPC-1 cells. Both 3D4 and trastuzumab significantly down-regulated the expression of pHER3, and two drug combination showed synergistic in-
hibitory effect. b. 3D4 significantly inhibited cellular proliferation at concentrations equal to 20 ug/ml or 50 μg/ml (P < 0.05)
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MSTs of patients with stump cancer, low differentiation,
adenocarcinoma, N1 stage, and CA 19-9 >1200U/ml were
significantly lower than those of patients from the
corresponding control subgroups (4.87 vs. 17.69 months,
P < 0.001; 9.34 vs. 33.21 months, P < 0.001; 13.38 vs.
49.18 months, P < 0.001; 11.57 vs. 34.65 months, P= 0.007;
10.59 vs. 32.88 months, P < 0.001; respectively). No signifi-
cant differences in MSTs were observed between subgroups
of sex, age, smoking history, drinking history, tumor family
history, tumor location, T stage, and M stage (Table 1).
HER family protein expression status among the different
patient subgroups
The Chi-square test was used to analyze differences in
HER family protein expression status between patient
subgroups. Significant differences in HER1 expression
status were observed between the sex subgroups (P =
0.027) and the differentiation subgroups (P = 0.026). A
significant difference in HER2 expression status was
observed between the CA 19-9 subgroups (P = 0.020).
Significant differences in HER4 expression status were
observed between the smoking history subgroups (P =
0.026), the drinking history subgroups (P = 0.042), the
pathology types subgroups (P = 0.014) and the T stage
subgroups (P = 0.017). However, significant differences
in HER3 expression status were not observed between
any subgroups (P > 0.05 in all cases; Table 2)
Association between HER family protein expression status
and patient survival
IHC analysis of patient tissue specimens revealed that
positive HER1, HER2, HER3 and HER4 expression was
observed in 41.4, 60.0, 24.3 and 65.7% of cases, respect-
ively. Differences in patient survival times between the
negative and positive expression subgroups for all HER
family proteins were analyzed by the Kaplan–Meier
method. The analysis showed that the MST for the
HER3 positive group was 12.0 months, which was sig-
nificantly lower than 25.6 months observed for the
HER3 negative group (P = 0.013). MST for the HER4
positive group was 25.6 months, which was significantly
higher than 11.4 months observed for the HER4 negative
group (P = 0.027). No significant association between
HER1 or HER2 expression status and survival time was
observed in our analysis (P = 0.626 & P = 0.859, respect-
ively; Fig. 3 and Table 3)
Evaluation of HER family protein expression status and
clinicopathological characteristics as independent
predictors of survival in operable pancreatic cancer
A large number of factors affected the survival time of pa-
tients with operable pancreatic cancer, and Cox’s multiple
regression analysis was performed to identify those factors
that were independent predictors of prognosis. HER
family protein expression status along with those clinico-
pathological parameters which demonstrated significance
Fig. 2 Representative images of HER1–4 tissue staining for all expression scores (0–3+) which were assigned according to the cytoplasm and
membrane-staining intensity (original magnification ×200)
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following univariate analysis were included in the Cox’s
multiple regression analysis. Risk of death for the HER3
positive group was 3.684 times greater than that for the
HER3 negative group (P = 0.001). Differentiation (RR
3.804, P = 0.006), histopathology type (RR 4.595, P =
0.013) and stump cancer (RR 10.110, P = 0.001) were also
independent predictors of survival. However, the expres-
sion status of HER1, HER2 and HER4, positive lymph
Table 1 The comparison of median survival time in different subgroups






Male 28 (40.0) 11.93 3.98
Female 42 (60.0) 16.64 6.11
Age 0.059
< 60 y 34 (48.6) 49.18 16.69
≥ 60 y 36 (51.4) 13.38 2.64
Tumor family history 0.795
Yes 5 (7.1) 11.21 0.68
No 65 (92.9) 16.64 4.38
Smoking history 0.591
Yes 13 (18.6) 17.23 11.98
No 57 (81.4) 15.88 4.18
Drinking history 0.902
Yes 7 (10.0) 17.22 7.88
No 63 (90.0) 15.88 4.41
Tumor location 0.256
Head 45 (64.3) 13.38 1.92
Body + tail 25 (35.7) 17.23 5.21
Stump cancer 0.000
Yes 6 (8.6) 4.87 0.73
No 64 (91.4) 17.69 8.53
Differentiation 0.000
Lower 17 (24.3) 9.34 2.91
Higher 53 (75.7) 33.21 18.47
Pathology type 0.001
Adenocarcinoma 53 (75.7) 13.38 1.68
Non-adenocarcinoma 17 (24.2) 49.18 1.02
T stage 0.188
T1 + T2 34 (48.6) 22.32 11.19
T3 + T4 36 (51.4) 12.07 2.20
N stage 0.007
N0 39 (55.7) 34.65 13.76
N1 31 (44.3) 11.57 0.79
M stage 0.092
M0 62 (88.6) 17.23 5.86
M1 8 (11.4) 7.66 4.67
CA19-9 0.000
< 1200 U/ml 57 (81.4) 32.88 9.20
> 1200 U/ml 13 (18.6) 10.59 3.29
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node number, N stage and CA 19-9 score could not inde-
pendently predict survival (P > 0.05 in all cases; Table 4).
Discussion
There are relatively few studies on the prognostic signifi-
cance of HER family members in patients with operable
pancreatic cancer. To date, the findings regarding the
prognostic significance of HER family protein expression
in pancreatic cancer have been inconsistent. This may
be a consequence of inter-study differences in tissue
preparation, the detection antibodies used, and different
methods of scoring. In our study we performed a
comprehensive analysis of the prognostic value of
HER1–4 in patients with operable pancreatic cancer.
Table 2 The expression of HER1 - HER4 in different subgroups


















Sex 0.027 0.258 0.564 0.164
Male 12 16 13 15 21 7 12 16
Female 29 13 15 27 32 10 12 30
Age 0.663 0.519 0.446 0.139
< 60 y 19 15 14 20 25 9 9 25
≥ 60 y 22 14 14 22 28 8 15 21
Tumor family history 0.338 0.671 0.237 0.563
Yes 2 3 2 3 5 0 2 3
No 39 26 26 39 48 17 22 43
Smoking history 0.094 0.579 0.389 0.026
Yes 5 8 5 8 9 4 8 5
No 36 21 23 34 44 13 16 41
Drinking history 0.310 0.085 0.220 0.042
Yes 13 4 5 2 4 3 5 2
No 28 25 23 40 49 14 19 44
Tumor location 0.856 0.127 0.589 0.409
Head 26 19 15 30 35 10 17 28
Body + tail 15 10 13 12 18 7 7 18
Pathology types 0.138 0.233 0.113 0.014
Adenocarcinoma 28 24 19 33 37 15 22 30
Non-adenocarcinoma 13 5 9 9 16 2 2 16
Differentiation 0.026 0.167 0.144 0.570
Lower 6 11 9 8 15 2 6 11
Higher 35 18 19 34 38 15 18 35
T stage 0.663 0.330 0.164 0.017
T1 + T2 19 15 15 19 28 6 7 27
T3 + T4 22 14 13 23 25 11 17 19
N stage 0.566 0.480 0.496 0.329
N0 23 16 15 24 29 10 12 27
N1 18 13 13 18 24 7 12 19
M stage 0.273 0.598 0.091 0.269
M0 35 27 25 37 49 13 20 42
M1 6 2 3 5 4 4 4 4
CA199 0.467 0.020 0.332 0.480
< 1200 U/ml 34 23 19 38 42 15 19 38
> 1200 U/ml 7 6 9 4 11 2 5 8
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Fig. 3 Kaplan–Meier survival curve analysis. Patients were categorized according to HER positive and negative expression status. Curves show overall
survival differences according to HER1 (a), HER2 (b), HER3 (c), and HER4 (d) expression status
Table 3 The cancer-specific survival and HER1 - HER4 expression
Variable Number (%) Mean value (months) Median survival time (months) P value (for median survival time)
HER1 0.626
Negative 41 (58.6) 34.0 17.7
Positive 29 (41.4) 31.4 14.3
HER2 0.859
Negative 28 (40.0) 33.4 15.6
Positive 42 (60.0) 35.1 15.9
HER3 0.013
Negative 53 (75.7) 39.1 25.6
Positive 17 (24.3) 18.1 12.0
HER4 0.027
Negative 24 (34.3) 24.5 11.4
Positive 46 (65.7) 40.6 25.6
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Kaplan–Meier analysis showed that the MST of the
HER3 positive group was 12.0 months, which was sig-
nificantly lower than 25.6 months observed for the
HER3 negative group (P = 0.013). Cox’s multiple regres-
sion analysis demonstrated that HER3 was an independ-
ent predictor of poor prognosis; risk of death associated
with HER3 positive expression was 3.684 times greater
than that associated with HER3 negative expression (P =
0.001). Although Cox’s multiple regression analysis did
not identify HER4 positive expression as an independent
predictor of survival, Kaplan–Meier analysis did show
that the MST of the HER4 positive group was
25.6 months, which was significantly higher than
11.4 months for the HER4 negative group (P = 0.027).
This suggests that HER4 may be of some potential prog-
nostic value in pancreatic cancer and this deserves fur-
ther attention. No significant association between HER1
or HER2 positive expression and survival were observed,
and neither receptor was a predictor of survival.
HER1 is overexpressed in a variety of human malig-
nancies [21, 22]. The frequency of HER1 expression in
pancreatic cancer has been reported as 30.4% [23] and
45.1% [25] in two previous studies. In our study HER1
expression was observed in 41.4% of patients. HER1
overexpression has previously been associated with de-
creased survival [23, 24], and the cumulative 1-, 3- and
5-year survival rates were 48, 20 and 18%, respectively
[24]. A previous meta-analysis has shown that three
trials reported a survival disadvantage for patients with
HER1 expression, while other five trials reported no sig-
nificant difference, however, the combined hazard ratio
was 1.225 (P = 0.035) [25]. Another meta-analysis drew
the opposite conclusion that HER1 was not a significant
prognostic factor in resected pancreatic cancer (HR =
1.35, 95% CI 0.80–2.27, P > 0.05) [26]. From our analysis,
we also drew the conclusion that positive HER1 expres-
sion has no prognostic value in operable pancreatic
cancer.
HER2 expression is associated with decreased disease-
specific survival and poor prognosis in patients with breast
cancer and gastric cancer [17, 18, 27]. The frequency of
HER2 expression and its association with survival in pan-
creatic cancer remains unclear. Te Velde et al. reported
that neither membranous overexpression nor gene ampli-
fication of HER2 was seen in pancreatic cancer [28]. A
study by Aumayr, et al. observed positive HER2 expres-
sion, as determined by IHC staining, in 10% of pancreatic
cancer cases, and of these, 7% demonstrated HER2 gene
amplification [29]. In our study we observed positive
HER2 expression in 60.0% of cases, which is significantly
higher than that observed by others. Komoto et al. re-
ported that patients with HER2 overexpression had sig-
nificantly shorter survival times than those with normal
HER2 expression (14.7 vs. 20.7 months, P = 0.008), and
multivariate survival analysis demonstrated that HER2
was an independent prognostic factor (HR 1.806; P =
0.026) [30]. In our study, however, no significant associ-
ation between HER2 expression and survival time was ob-
served, and there was no prognostic value associated with
positive HER2 expression.
Our study has confirmed the high expression of pHER3
in the AsPC-1 pancreatic cancer cell line by western blot-
ting, and anti-HER3 monoclonal antibody could signifi-
cantly down-regulated pHER3 level. Furthermore, the
treatment of AsPC-1 cells with increasing concentrations
of anti-HER3 monoclonal antibody resulted in significant
inhibition of cellular proliferation. HER2/HER3 heterodi-
mers are reported to be activated in pancreatic cancer
[31], the fact that anti-HER3 monoclonal antibody (3D4)
and anti-HER2 monoclonal antibody (trastuzumab) syner-
getic down-regulated pHER3 in the AsPC-1 cell indirectly
proved the simultaneous inactivation of HER2/HER3
heterodimers. These results of Thomas G et al. and our
study are identical. However, the diverse coexistence of
HER family homo or heterodimers (HER2/HER2, HER1/
HER2, HER1/HER3 and HER2/HER3) and differences in
Table 4 Cox’s multiple regression analysis for survival time
Variable Relative risk 95% confidence interval P value
HER1 positive vs. negative 0.598 0.281–1.271 0.181
HER2 positive vs. negative 0.909 0.420–1.968 0.809
HER3 positive vs. negative 3.684 1.732–7.834 0.001
HER4 positive vs. negative 0.800 0.375–1.710 0.565




Differentiation poor vs. well 3.804 1.480–9.774 0.006
N stage N1 vs. N0 0.661 0.259–1.685 0.386
The positive lymph node number 1.331 0.964–1.838 0.083
CA199 >1200 U/ml vs. <1200 U/ml 1.961 0.806–4.770 0.138
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detection methods may explain the non-parallel expres-
sion of HER2 and HER3. Studies on the predictive value
of HER3 expression on patient outcome in solid tumors
are limited. A meta-analysis has reported HER3 overex-
pression in 42.2% of solid tumors [32] and an association
between HER3 expression and worse overall survival at
both 3 years (OR = 2.24, P < 0.001) and 5 years (OR = 2.20,
P < 0.001) [32]. Thomas et al. reported that HER3 was
expressed in 27% of the 45 cases of pancreatic ductal
adenocarcinoma, which was similar to the 24.3% reported
in our study [31]. The study by Thomas et al. showed that
HER3 expression was essential for pertuzumab efficacy in
HER2low pancreatic cancer, and that HER3 expression
may be a predictive biomarker for pertuzumab efficacy
[31]. Hirakawa at al. reported that the MST for patients
with curatively resected pancreatic cancer associated with
HER3 overexpression was 37.2 months, while that for
HER3-negative patients was 58.6 months (P = 0.008) [20],
the findings was similar to those of our study; our Cox’s
regression analysis demonstrated that the risk of death as-
sociated with HER3 positive expression was 3.684 fold
greater than that associated with HER3 negative expres-
sion. We therefore conclude that HER3 is a novel inde-
pendent prognostic biomarker for poor survival in
patients with pancreatic cancer.
Clinical research reports on the significance of HER4
expression in the prognosis of patients with solid tumors
are less numerous than for other HER family members.
It has been reported that the level of HER4 in pancreatic
cancer specimens, as determined by IHC, has no associ-
ation with patient survival [33]. A study by Thybusch-
Bernhardt et al. suggested that HER1 and HER2 overex-
pression contributes to a more aggressive phenotype and
that lack of HER4 expression may increase the meta-
static capacity of pancreatic cancer cells [34]. This is
consistent with our finding that the MST for the HER4
positive patient group was significantly higher than that
for the HER4 negative group (25.6 vs. 11.4 months, P =
0.027). Moreover, HER4 expression was negatively asso-
ciated with adenocarcinoma, which was shown to be a
poor outcome indicator in our study. However, Cox’s re-
gression analysis did not identify HER4 as an independ-
ent predictor of survival.
Conclusions
In conclusion, our study shows that HER3 is a novel in-
dependent prognostic marker for patients with operable
pancreatic cancer. There is a potentially positive advan-
tage associated with HER4 expression which deserves
further attention. The prognostic significance associated
with HER1 and HER2 expression in operable pancreatic
cancer was not found. By analyzing the expression of all
HER family members together within a single study en-
able us to ensure consistency in specimen processing,
detection, and scoring methods. This approach enables
more robust conclusions to be drawn when comparing
the prognostic significance of the single HER family pro-
teins. However, our study is limited by the small number
of cases, and a larger cohort prospective study is neces-
sary to confirm our conclusions. The interactions among
ligands, HER family members and downstream signaling
molecules are intricate, and the patterns of coexpression of
the signaling molecules will need to be taken into account
to fully understand the prognostic significance within a
given disease context. Advances in detection technology and
standardization of diagnosis criteria will continue to improve
methods for determining the prognostic value of HER fam-
ily members in operable pancreatic cancer.
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